

Format for ANSWERING REVIEWERS



January 21, 2014

Dear Editors,

Please find enclosed the edited manuscript in Word format (file name: 8411-review.doc).

Title: Anti-hypertensive drugs in children and adolescents

Author: Patricia Y. Chu, Michael J. Campbell, Stephen G. Miller, Kevin D. Hill

Name of Journal: *World Journal of Cardiology*

ESPS Manuscript NO: 8411

We thank the reviewers for their thoughtful comments. The manuscript has been revised according to the suggestions of reviewers and we feel is significantly improved. We have used 'track changes' to document changes in the resubmitted manuscript. To summarize changes:

1. The format has been updated. As requested, a figure that is decomposable has been attached as a powerpoint file.

2. Revision have been made according to the suggestions of the reviewer

(1) In response to Reviewer #1's comments. We have changed the title to be more representative of paper. We have added a sentence in the conclusion to underscore how pediatric trials resulted in differences between children and adults in which antihypertensive drugs are used. More specifically, irbesartan and bisoprolol, which are approved for adult hypertension are not approved for pediatric hypertension. We appreciate the reviewers suggested additions to Table 2; however multiple trials were performed for each of these drugs and we could not feasibly add all of the requested information to the table. Instead we have worked to make the text more concise by removing the trial design information, which is already covered in Figure 1.

(2) In response to Reviewer #2's comments. We have added a section in the introduction describing our sources of research and key words used for the literature search. A column describing the most common adverse events associated with each class of medications was added to Table 2. Severe adverse events did not occur in pediatric trials, possibly due to the shorter duration of the trials. However, potential severe adverse events seen in adult populations are covered under the precautions section. We have commented in the conclusion on the differences between pediatric and adult trial data.

3. References and typesetting were corrected

Thank you again for considering our revised manuscript for publication in the *World Journal of Cardiology*.

Sincerely,

A handwritten signature in black ink, appearing to read "Kevin D. Hill". The signature is fluid and cursive, with a large loop at the end of the last name.

Kevin D. Hill, MD MSCI
Duke Clinical Research Institute
2400 Pratt Street, Room 7582 Box 3850
Durham, North Carolina 27705
Office: 919.668.8305
Fax: 919.681.9457
Email: kevin.hill@duke.edu